Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms × GSK2110183 × Clear all

Phase

Phase 2 2 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

pembrolizumab 44 Nivolumab 28 Gemcitabine 28 Paclitaxel 19 Cisplatin 18 Ipilimumab 14 Carboplatin 14 Cyclophosphamide 13 Capecitabine 12 Dexamethasone 10 Bevacizumab 10 Irinotecan 9 Docetaxel 9 Albumin-Bound Paclitaxel 9 130-nm albumin-bound paclitaxel 9 spartalizumab 8 cemiplimab 8 Pemetrexed 8 Sorafenib 7 Rituximab 7 Cetuximab 7 fludarabine 6 Temozolomide 6 Taxes 6 Radiotherapy 6 Leucovorin 6 Fluorouracil 6 Azacitidine 6 Ascorbic Acid 6 lenvatinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01653912 2018-04-02

Dose-finding Study in Platinum-Resistant Ovarian Cancer

Accenture

Phase 1/2 Completed

59 enrolled 18 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡